High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer.


Journal

Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 13 03 2019
accepted: 12 07 2019
pubmed: 24 9 2019
medline: 28 2 2020
entrez: 24 9 2019
Statut: ppublish

Résumé

The interaction between tumor necrosis factor receptor superfamily, member 4 (OX40) on T cells and the OX40 ligand (OX40L) on antigen‑presenting cells (APCs) is a pivotal step for T‑cell activation and the promotion of antitumor immunity. However, it is hypothesized that soluble OX40 (sOX40) in blood suppresses T‑cell activation by blocking the OX40/OX40L interaction. In the present study, the association between blood sOX40 levels and the clinical characteristics of advanced colorectal cancer (CRC) patients was investigated. Blood was collected from 22 patients with advanced CRC. Blood sOX40 levels were determined by enzyme‑linked immunosorbent assay (ELISA). Messenger RNA (mRNA) expression encoding OX40 or cytokines was analyzed by quantitative RT‑PCR. Blood sOX40 levels were positively correlated with the blood levels of carbohydrate antigen (CA) 19‑9, carcinoembryonic antigen (CEA), C‑reactive protein (CRP) and soluble programmed cell death ligand‑1 (PD‑L1) in patients but negatively correlated with the blood levels of albumin. Blood sOX40 levels were not correlated with the mRNA expression of interferon (IFN)‑gamma, interleukin (IL)‑6, IL‑10 and IL‑4 in the peripheral blood mononuclear cells (PBMCs) of the patients and were not correlated with the frequency of programmed cell death‑1 (PD‑1) expressing CD4+, CD8+ and CD56+ cells. Notably, according to both univariate and multivariate analyses, high blood sOX40 levels were significantly correlated with a reduced survival time in patients. Although activated Jurkat cells (a human T cell line) exhibited an upregulation of sOX40 production and OX40 mRNA expression, the OX40 mRNA expression of the PBMCs of patients was not correlated with blood sOX40 levels. High blood levels of sOX40 were correlated with a reduced survival time in patients with advanced CRC, possibly associated with the suppression of antitumor immunity by sOX40.

Identifiants

pubmed: 31545443
doi: 10.3892/or.2019.7304
doi:

Substances chimiques

Antigens, Tumor-Associated, Carbohydrate 0
Carcinoembryonic Antigen 0
Organothiophosphorus Compounds 0
Receptors, OX40 0
TNFRSF4 protein, human 0
carbohydrate antigen 199, human 0
C-Reactive Protein 9007-41-4
phosfolan CHJ98J84AY
Serum Albumin, Human ZIF514RVZR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2057-2064

Auteurs

Ryoichi Sawada (R)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 105‑8461, Japan.

Yoshinori Arai (Y)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 105‑8461, Japan.

Yukiko Sagawa (Y)

Division of Oncology, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo 105‑8461, Japan.

Yusuke Nagata (Y)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 105‑8461, Japan.

Takashi Nishimura (T)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 105‑8461, Japan.

Masaaki Noguchi (M)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 105‑8461, Japan.

Katsushi Amano (K)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 105‑8461, Japan.

Seiji Arihiro (S)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 105‑8461, Japan.

Masayuki Saruta (M)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 105‑8461, Japan.

Sadamu Homma (S)

Division of Oncology, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo 105‑8461, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH